Search
for
Sort by
Research 271–300 of 1000+
- Allergen‐specific immunotherapy improves alopecia totalis in a severe atopic dermatitis patient
- Case report: NUDT15 polymorphism and severe azathioprine-induced myelosuppression in a young Chinese female with systematic lupus erythematosus: a case analysis and literature review
- Association of androgenetic alopecia with a more severe form of COVID-19 infection
- Immunotherapy for resistant and/or severe alopecia areata in a university hospital setting in Northern Mexico
- Alopecia en mujeres con obesidad severa y mórbida sometidas a cirugía bariátrica Alopecia in women with severe and morbid obesity who undergo bariatric surgery
- Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults
- Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report
- Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report
- 75122 Real-world Effectiveness of Baricitinib for Severe Alopecia Areata by Baseline Hair Loss and Episode Duration: Results from a Prospective Observational Study
- COMPARISON OF CLINICAL EFFICACY OF TOFACITINIB VERSUS METHOTREXATE IN SEVERE ALOPECIA AREATA, ALOPECIA TOTALIS, AND ALOPECIA UNIVERSALIS: A RANDOMIZED CONTROLLED TRIAL
- Adis Summary of Research: Improvement in measures of quality of life and symptoms of anxiety and depression in patients with severe alopecia areata achieving sustained scalp hair regrowth with baricitinib
- PA11 A rare case of a severe papulopustular dermatosis secondary to a germline <i>EGFR</i> mutation
- Diagnosis and therapeutic management of severe generalized demodicosis complicated by deep bacterial pyoderma in dog: A case report
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis
- Retrospective Comparison of Inflammatory Markers in Severe Acne Vulgaris Patients and Normal Population
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Efficacy of oral tofacitinib in moderate to severe alopecia areata, totalis and universalis at the tertiary care hospital, Karachi
- Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
- 62339 Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- 60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction